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Although the trauma setting virtually defines
major risk for venous thromboembolism (VTE),
scanty data exist among prospective studies1-9 to
guide the surgeon in the selection of the optimal
methods of prophylaxis (PRx) or in the use of
surveillance diagnostic studies such as venous
Doppler ultrasound scanning (VDUS).1,4,10-14
Anticoagulation therapy with low molecular
weight heparin (LMWH) appears to be evolving as
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Purpose: This study was done to evaluate the use of published standardized risk factors
for venous thromboembolism (VTE) in patients admitted to a trauma intensive care unit
(ICU) and to derive guidelines for the use of low molecular weight heparin (LMWH)
and surveillance venous Doppler ultrasound scanning (VDUS).
Methods: Patients were admitted to a regional trauma center ICU. Two periods were
studied. Period 1 was a retrospective analysis of documented cases of VTE in the trauma
registry from 1993 to 1995 (n = 39). The period was also a review of all patients
admitted to a trauma ICU in 1994 without VTE who met the following criteria: age
greater than 11 years, ICU stay of more than 36 hours, and survival of more than 72
hours (n = 227). Period 2 was a concurrent analysis of 1996 documented cases of VTE
and similarly selected ICU admissions (VTE, n = 10; no VTE, n = 224). Risk factor
scores (R1, admitting; R2, total) were calculated from the International Society for
Cardiovascular Surgery/Society for Vascular Surgery reporting standards. The scores
were cumulative by category and over time. The suitability of such standards was deter-
mined in period 1. The resulting therapeutic and surveillance guidelines were evaluated
in period 2.
Results: Period 1 risk factor scores, R1 and R2, were correlated with the occurrence of
VTE from c 2 test (P < .05 and P < .01, respectively). Risk categories were grouped as
low, moderate, and high. VTE was not observed in the low-risk group (0 to 2). Among
all VTE (n = 49), 11 cases occurred in patients with moderate-risk scores and 38 in
patients with high-risk scores. In 1994 and 1996, the selected groups were analyzed and
the incidence rate of VTE was 4.7% in both years for the moderate-risk group and 2.5%
and 4.8% for the high-risk group, respectively.
Most VTE cases (78%) received some form of prophylaxis (PRx), and 26% of cases had
multiple methods of prophylaxis (MPRx). This included 80% of the cases that received
unfractionated heparin.
In period 2, no pulmonary emboli (PE) occurred, in contrast to period 1, in which 16
of 39 cases of VTE (41%) were first seen with PE. In period 2, no patient receiving
MPRx, including compression and LMWH, had VTE develop. Surveillance VDUS
discovered 60% of 1996 cases in period 2. No PE were seen in period 2.
Conclusion: Standard risk factors were easily applied to the trauma patient at the bedside.
Patients at low risk needed no PRx. Patients at high risk did best with both compres-
sion devices and LMWH. VDUS was recommended selectively in patients at high risk in
whom multiple-method PRx could not be achieved. Patients at moderate risk required
further study to define optimal PRx and need for surveillance VDUS. Intracaval devices
were used prophylactically only twice. (J Vasc Surg 1998;28:250-9.)
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the most effective chemical method.1,2,8,15 This
method is also the most expensive and may 
be limited in applicability, especially in cases of
neurologic or major pelvic trauma. Compression
devices are reported to have varying success in the
trauma setting, particularly for neurologic trauma.
1,4-6,8,11,12,16,17 Data regarding multiple-method
PRx are conflicting.4,6,8
The diagnosis of VTE is complicated by the
frequent absence of symptoms in the continuum of
its major manifestations.18,19 VDUS, phlebography,
and magnetic resonance angiography—all have been
studied and advocated.1-4,20-24 However, the over-
riding concern among these choices has been their
cost and effectiveness.1,2,8,10,11,13,25,26
The lack of standardized risk factors and patient
stratification according to risk does not allow
comparisons between reports from different institu-
tions. Although many studies accept the major risk
factors defined by the National Institutes of Health
and European consensus studies,27,28 most define
individual factors rather than a cumulative risk. As a
result, data reduction tends to eliminate known risk
factors, as seen in the recent summary of studies by
Knudson.4 Published reporting standards of risk,
which are cumulative in their score,29 have not been
systematically applied. This study was begun to eval-
uate the use of the International Society for
Cardiovascular Surgery/Society for Vascular Surgery
(ISCVS/SVS)29 reporting standards of VTE risk in
the trauma setting. Guidelines then were derived for
the use of single-method and multiple-method PRx
and the indication for surveillance VDUS.
MATERIAL AND METHODS
All patients in this study were admitted to a level
II trauma center serving northern Nevada and the
eastern Sierra slope of California. Approximately
2000 patients were admitted for trauma annually
during the study (92% blunt trauma, 8% pene-
trating). Intensive care unit (ICU) admissions for
trauma varied from 430 to 470 per year; the general
demographics were similar from year to year. A panel
of 10 trauma surgeons staffed this unit, with 2
specialized trauma nurse coordinators.
In period 1, all documented cases of VTE were
reviewed retrospectively from 1993 through 1995
(n = 39). In addition, patients in trauma ICU (age
more than 11 years, survival more than 72 hours,
and ICU stay more than 36 hours) who did not have
VTE were studied retrospectively for 1994 as a
denominator (n = 227). In period 2 for 1996, all
cases of documented VTE (n = 10) and similarly
selected ICU cases without VTE (n = 224) then
were tracked concurrently.
Risk factors used were adopted from the
reporting standards recommended by the
ISCVS/SVS in 1988,29 with slight modifications to
suit the trauma setting. The risk factor grades were
cumulative both at admission and over time as
published. Delayed diagnoses and multiple opera-
tions (up to 3) were included in the total score, R2.
The following factors and grades were defined:
Age: 0 to 39 years = 0, 40 to 69 years = 1, ‡ 70
years = 2
Long bone fracture: none = 0, soft tissue = 1,
tibia, fibula, arm = 2, femur = 3, pelvis = 4
Immobilization: none = 0, 1 to 3 days = 1, >3
days = 2, paraplegia or quadriplegia = 3
Anesthesia time: none = 0, local or <45 minutes
= 1, <3 hours = 2, >3 hours = 3
Prior VTE: none = 0, suspected = 1, proven = 2,
multiple = 3
Individual risk factors that were not immediately
apparent at admission or from the records, such as
obesity or the presence and degree of heart disease
or cancer, were simplified as present = 1 and absent
= 0. The remaining recommended risk factors rarely
were encountered and, therefore, were omitted from
this analysis.29
Table I. Occurrence of venous thromboembolism from 1993 to 1996 by low-risk, moderate-risk, and
high-risk categories
All VTE 1993 (No. PE) 1994 (No. PE) 1995 (No. PE) 1996 (No. PE) Total (No. PE)
Low risk 0-2 0 0 0 0 0
Moderate risk 3-5 2 (2) 4 (1) 1 (1) 4 (0) 11 (4)
High risk ‡ 6 19 (8) 3 10 (3) 6 (0) 38 (11)
Total 21 7  11  10 49 (15) 
*Percent of all ICU 
admissions 4.5% 1.6% 2.2% 2.1%
VTE, venous thromboembolism; PE, pulmonary emboli; ICU, intensive care unit. *Relative incidence rate of venous thromboembolism
for all admissions is indicated on the bottom line.
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An initial score R1 was derived. This score was
the sum of the various factors known to the trauma
team on morning rounds after the patient was
admitted to the ICU. In period 2, the PRx require-
ments and need for surveillance then were deter-
mined. Total risk R2 was the sum of all risk factors
at the time of discharge, death, or a VTE event.
From analysis of the descriptive scores in period 1
data, the risk categories were defined arbitrarily as
follows: low = 0 to 2 factors, moderate = 3 to 5
factors, and high = 6 or more factors. A score of 15
was the maximum score possible. Direct venous
injury and upper-extremity VTE were omitted to
focus the analysis on lower-extremity VTE.
The staff agreed on guidelines for PRx as a result
of period 1 descriptive data. These guidelines were
accepted as follows: scores of 0 to 2 did not need PRx
other than early ambulation and moderate-risk scores
of 3 to 5 received compression devices, sequential
compression devices or AVI foot compressors, which
were placed in the operating room or ICU.
Enoxaparin alone was considered an acceptable alter-
native. Compression devices and LMWH or
Enoxaparin were advised for patients with risk scores
of 6 or more. LMWH therapy was begun as soon as
possible after admission, with 30 mg being given
subcutaneously every 12 hours. Period 1 experience
revealed that 8 of 10 patients for multiple-method
PRx with documented VTE had received unfraction-
ated heparin. In 1995, only 2 cases of VTE were
documented with LMWH as the second method,
which suggests more liberal use of this agent.
Whenever optimal PRx was not possible, routine
VDUS was advised. Studies were done at days 5 to
7 and then weekly until patients were ambulant.
VDUS was done in a registered noninvasive labora-
tory and interpreted independently by a panel of 9
vascular surgeons. Three of these participated on
the trauma team, but they did not know which
patients received PRx.
Surveillance lung scanning was not done.
Intracaval devices were considered in patients at
high risk with a score of 10 or more and, particularly,
in patients with head injuries with a contraindication
to anticoagulants and patients with major pelvic frac-
tures. Otherwise, standard indications for deep
venous thrombosis (DVT) or pulmonary emboli
(PE) were used for filter placement.
Demographics for all trauma ICU admissions
and the defined-risk ICU admissions were analyzed
with Student’s t test. Nonparametric data were
compared with c 2 test.
RESULTS
In period 1, the initial risk factor score, R1 (P <
.05), and total risk factor score, R2 (P < .01), corre-
lated with the occurrence of VTE by c 2 test. The
demographics of all trauma ICU admissions for the
4 years studied were similar except for the length of
stay. Because of deliberate efforts of the trauma team
and utilization committees, the length of stay was
reduced by approximately 24 hours in 1996.
Table I shows the occurrence of VTE as classified
by year and risk categories. To date, no instance of
VTE has been detected in the low-risk group (0 to
2 factors). Eleven cases of VTE were seen in the
moderate-risk group; 4 had PE in period 1, and 1
case was fatal. Most VTE cases occurred in the high-
risk group (n = 38, 77.5%). Twelve PE were seen in
period 1, and 4 cases were fatal.
In period 1, VTE cases were documented by
means of VDUS or ventilation-perfusion scanning
or autopsy in the 5 cases of fatal PE. For the years
with a selected baseline group, the incidence rate of
VTE was 4.7% in the moderate-risk group for both
1994 and 1996. The incidence rate for the high-risk
Table II. Annual occurrence of venous thromboembolism in patients at moderate risk and high risk as
related to prophylactic methods
Risk PRx 1993 1994 1995 1996 Total
Moderate None 1 2 3
Moderate SCD 1 2 1 4 8
Moderate MPRx 0 0 0 0
High ‡ 6 None 3 0 0 0 3
High ‡ 6 SCD 13 2 6 4 25
High ‡ 6 MPRx 3 1 4 (2*) 2 10 (2*)
Total 21 7 11 10 49
PRx, prophylaxis; SCD, sequential compression device or air velocity index boot; MPRx, multiple-method prophylaxis (SCD and anti-
coagulants). *Number of patients who received low molecular weight heparin.
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group was 2.5% and 4.8%, respectively. The infre-
quency of surveillance VDUS in period 1 prohibits
quantitative conclusions regarding the true inci-
dence rate of VTE in that time. However, once
again, PE occurred in 5 instances as the first indica-
tion of VTE in period 1. No cases of PE were docu-
mented in 1996. The occurrence of VTE by year is
shown for year to year comparison, with all unse-
lected ICU admissions (range, 430 to 470) for 1993
(n = 21, 4.5%), 1994 (n = 7, 1.6%), 1995 (n = 11,
2.2%), and 1996 (n = 10, 2.1%). Essential popula-
tion demographics were age, Injury Severity Scores
(ISS), Glascow Coma Scale (GCS), and ICU stay.
These were similar, except as noted for length of stay
in 1996.
Table II shows the annual occurrence of VTE
cases by risk category and PRx. No cases of VTE
were observed in the low-risk group. Six cases of
VTE received no PRx (period 1); these cases were
distributed equally between moderate-risk and high-
risk scores. Eight of the 11 moderate-risk VTE cases
had used compression devices. Two thirds of the
high-risk group with VTE received compression
devices only. In period 1, 10 cases of VTE received
multiple-method therapy, but in only 2 instances in
1995 was the second method LMWH. The
remainder received unfractionated heparin at 8-hour
or 12-hour intervals.
Table III shows selected designated-risk ICU
cases without VTE admitted in 1994 and 1996 on
the basis of the criteria of age (>11 years), ICU stay
(>36 hours), and survival (>72 hours). This analysis
was done to select the patients with the highest risks.
The mode of PRx is illustrated along with the risk
category. The number of patients at high risk who
received only compression devices decreased from
68 (59%) in period 1 to 44 (37.3%) in 1996. At the
same time, the number of patients who received
multiple-method PRx increased from 43 (37%) to
71 (60.2%; P < .01, by c 2 test). Enoxaparin was used
as the additional method in 58% of cases in 1994
and 94.4% of cases in 1996 (P < .01, by c 2 test).
Table IV indicates the percentage VTE by PRx
and risk category for the 2 years with baseline
denominator. The numbers do not permit statistical
analysis. The relatively even distribution of VTE
between patients at moderate and high risk in the
even years, compared with the greater proportion of
patients at high risk with VTE in the odd years, is
noted. No documented cases of VTE were seen in
the low-risk group or in those patients culled from
the selected ICU denominator group.
The selected ICU admissions (1994 vs 1996)
without VTE were essentially similar in average age
(37 vs 36.8 years), ISS (19 vs 19.1), and ICU length
of stay (7.9 vs 7.0 days). Overall, the patients for
VTE were older, by 42 years, and had longer ICU
stays, by 17.3 days. No significant differences in ISS
were found in patients with and without VTE
(average with VTE, 18; without VTE, 19). Long
ICU stays are reflected in the score, particularly in
immobilization. The numerically based guidelines
for PRx derived from period 1 data were presented
and discussed by the trauma panel in late 1995.
Emphasis then was placed on the use of LMWH
rather than unfractionated heparin. At the same
time, the use of routine surveillance VDUS was
recommended whenever optimal PRx was not or
could not be achieved; nearly all patients received
compression devices. In period 2, compliance with
guidelines occurred in 89% of the cases. The
noncompliant cases (26 of 234 admissions) included
2 patients in period 2 in whom VTE occurred.
Noncompliance was tabulated when no anticoagula-
tion therapy was used, and the VDUS surveillance
guidelines were not observed. Bleeding and high-
risk neurologic injury were the most common
reason for no Enoxaparin.
Surveillance VDUS increased in period 2 and
was performed in 72 instances in 1996 as compared
with 44 times in 1994. In 1993, only 1 of the 21
VTE was discovered with surveillance as compared
with 60% of those discovered in 1996. In those 4
years, 10 patients had DVT confined to the calf, 60%
of which were discovered with surveillance. Thirty
patients exhibited DVT in the proximal vessels, with
or without calf involvement. Twenty-four patients
had DVT that was diagnosed clinically. Only 6 cases
were discovered with surveillance, whereas 50% of
cases of proximal DVT in 1996 were discovered
with surveillance. The location of DVT was
unknown in 9 cases of PE in which the VDUS study
was either not done or peripheral extremity
thrombus was not shown.
Vena cava filters were used infrequently in this
experience. Of the 14 placed, only 2 were done
prophylactically. Twelve were inserted for standard
indications, such as DVT or PE when anticoagula-
tion therapy was contraindicated. Complications
after filter placement included the development of 3
new instances of DVT, 1 extension of an established
DVT, and 1 nonfatal PE.
DISCUSSION
The aim of this study was to simplify and quan-
tify risk factors to allow the rational selection of
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methods of PRx for VTE and selective use of VDUS
in VTE detection. This study did not address desir-
ability of one particular form of PRx over another.
The relatively low incidence rate of VTE overall
reflects the staff education30 and use of conferences
devoted to VTE PRx by the trauma service. The first
conference preceded data collection begun in 1993,
with yearly updates of the data. As a result, the
applicability of the standardized risk factors among
this group was familiar and more readily accepted.
The true incidence rate of VTE is obscured, partic-
ularly in period 1 where data collection was retrospec-
tive, surveillance VDUS was sporadic, and overall
denominators were unavailable for analysis for 1993 or
1995. The apparent decrease in VTE severity in period
2 only suggests the efficacy of MPRx. Surveillance-
diagnosed silent VTE clearly increased (60% in 1996). 
A close relationship between trauma and VTE
initially was described by McCartney31 as early as
1934. Successful prevention of VTE, with heparin
in surgical cases, was summarized by Murray32 in
1947. An unacceptably high incidence rate of VTE
in trauma patients without PRx has been docu-
mented by Sevitt and Gallagher33 and Kudsk et
al.24 Most recently, Geerts et al2 showed an inci-
dence rate of up to 77% of DVT when major head
injury and lower-extremity fracture were
combined. Geerts concluded that all trauma
victims with an ISS of more than 9 should receive
some form of PRx, confirming the recommenda-
tion by Hoyt and Swegle34 that all patients in ICU
should have VTE PRx. 
Discrepancies in the literature derive from a lack of
a standardized definition of high risk in the trauma
patient. Trauma enhances risk for VTE. Lack of quan-
tification renders comparisons of the results reported
by different institutions difficult. The high costs of the
emerging optimal PRx, such as LMWH,35,36 and of
surveillance VDUS10,11,20 make rational selection an
important consideration. The current system, graded
by severity, cumulative by risk factors, and on the basis
of published reporting standards (ISCVS/SVS
Subcommittee on Reporting Standards in Venous
Disease),29 was found to be both practical and easily
applied in the clinical setting.
A graded cumulative risk scoring system for VTE
PRx is not original and was applied to general
surgery by Farmer and Smithwick37 in 1950. This
system subsequently was adapted successfully for
orthopedic trauma by Tubiana and Duparc38 in
1961. Both authors cited cost and complexity of
PRx as justifying the need for a selective process.
The correlation with VTE of the current modifica-
tion of the ISCVS/SVS scoring system in period 1
was clear. The concurrent application of scores to
each new ICU admission in period 2 proved to be
easily accomplished, and different team members
readily agreed on scores. 
Subsequent updating of the score allowed the
inclusion of additional data as the clinical course
evolved. The second risk, R2, assessed cumulative
risk for each surgical procedure when multiple oper-
ations were required. About 20% of patients were
moved into a higher risk category by a delayed or
second operative procedure, such as spine fixation.
The failure to react to the upgraded score possibly
resulted in the occurrence of VTE in 2 of the period
2 cases. No scoring provision, however, exists for a
Table III. Prophylaxis used in selected cases* without venous thromboembolism during 1994 and 1996 in
low-risk, moderate-risk, and high-risk categories
1994 No PRx SCD MPRx LMWH Total
Low risk 0-2 9 22 0 0 31
Moderate risk 3-5 13 58 10 2 81
High risk ‡ 6 4 68 43** 25** 115
Total 26 148 53 227
1996 No PRx SCD MPRx Total
Low risk 0-2 12 12 0 0 24
Moderate risk 3-5 7 68 7 4 82
High risk ‡ 6 3 44 71** 67** 118
Total 22 124 78 224
PRx, prophylaxis; SCD, sequential compression device or air velocity index boot; MPRx, multiple-method prophylaxis (SCD and anti-
coagulants); LMWH, low molecular weight heparin.
*In these selected cases, age was >11 years, intensive care unit stay was >36 hours, and survival was >72 hours.
** Note increased prevalence of low molecular weight heparin use and multiple-method prophylaxis for high-risk group.P < .01 by
c
2 test for each.
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physiologic “second-hit”, such as septic shock, and
perhaps this refinement is needed. Such events can
prolong immobility and trigger the clotting cascade.
A second underassessment occurred in a young
patient with spinal cord injury caused by a diving
accident who did not undergo major surgery.
The basic risk groups, low, moderate, and high,
were derived in period 1 by retrospective analysis of
documented VTE for 3 years. The selection of the
group of patients in the ICU from 1994 sought to
eliminate young children, overnight ICU stays, and
early mortality rates. Overall, the VTE occurred as
follows: none in low-risk group, 25% in moderate-
risk group, and 75% in the high-risk group.
Discrimination by score between VTE occurrence
and no VTE was not observed in the preliminary data
from the multi-institutional study by Greenfield et al.8
The complexity of the scoring procedure suggested in
that study may make application at the bedside by
trauma personnel more difficult. Because we made no
preliminary determination of heparin/no heparin, we
cannot compare our data with several other reports
that address this issue.1,3,8 Most of our patients at
high risk who received compression therapy alone
would fall into the no-heparin category, according to
the criteria used by Knudson1 and Greenfield,8 but
not necessarily that used by Geerts.3
The surveillance program in period 2 appears to
have contributed to the absence of PE and is
consistent with the recent report by Brasel et al.13
These authors suggest that VDUS screening was
more cost-effective than routine caval filter place-
ment. The trend for more of the patients at high
risk in 1996 to receive multiple-method PRx,
particularly the use of LMWH (Enoxaparin), was
statiscally significant. Enoxaparin was chosen
because of the strong support from the orthopedic
literature combined with experiences with heparin
failure as the second method early in the study.
This choice is supported by the Canadian study by
Geerts,3 which shows the superiority of LMWH
over unfractionated heparin. Knudson et al1 also
have shown that Enoxaparin was most effective in
their patients who were candidates for anticoagu-
lants. The preliminary data of the Greenfield et al8
effort also seem to confirm this opinion.
The major problem in these studies of trauma and
VTE is the determination of eligibility for use of anti-
coagulants in patients with neurotrauma. The
Canadian3 study included “…all but frank intracra-
nial bleeding on computed tomographic scan-
ning…or bleeding that remained uncontrolled 36
hours after the injury” or “indications of coagu-
lopathy”. The study included patients with “cerebral
contusion, localized petechial hemorrhages, or
diffuse axonal damage. “Knudson1 criteria excluded
a GCS of less than 8, spinal cord injury, and nonop-
erative management of liver and spleen injuries.
Greenfield8 excluded intracranial bleeding by means
of computed tomography, incomplete or progressing
spinal cord injury, pelvic trauma requiring 2 or more
units of blood, nonoperative management of liver
and spleen injuries, and other considerations.
Hamilton et al39 note that “…adequate prophy-
laxis is underutilized in contemporary neurosurgical
practice” and that LMWH may be used safely.
Further dialogue with our neurosurgical colleagues
might increase the routine use of multiple-method
PRx in this problematic group of patients. For the
high-risk head-injury group with a contraindication
to LMWH, a decision rests between compression
devices and surveillance versus intracaval filters, as
discussed by Rodgers,26 Winchell,25 Kansarina,40
and Patton.41 Knudson1,4 found in her studies that
sequential compression devices were helpful in head
injuries as compared with no PRx. Gersin9
concluded that such devices were “not entirely effec-
tive”. We concur with the latter opinion inasmuch as
25 of 38 patients at high risk who were documented
in the current study with VTE had this form of PRx
Table IV. Incidence rates of venous thromboembolism in years with baseline data
Year 1994 1996
VTE/no. patients VTE/no. patients VTE/no. patients VTE/no. patients
Risk SCD % MPRx % SCD % MPRx %
Moderate 2/60 3.3 0/10 4/72 5.5 0/7
High 2/70 2.9 1*/44 2.3 4/48 8.3 2*/73 2.8
VTE, venous thromboembolism; SCD, sequential compression device or air velocity index boot; MPRx, multiple-method prophylaxis (SCD
and anticoagulants).  In 1994, 2 of 7 (13.3%) venous thromboembolism events were in patients at moderate risk with no prophylaxis.
Venous thromboembolism was not documented in the patients at low risk or in the patients selected from the intensive care unit group.
*Standard heparin in all cases.
only. More extensive use of LMWH might solve part
of this problem provided that costs are not excessive.
The multi-institutional study of Greenfield et al8 will
further clarify the use of the filter in these situations.
A troublesome finding in the current study was
the relatively high frequency of VTE in the
moderate-risk group in whom compression devices
would have been thought to be adequate. These
occurrences were clustered in 1994 and 1996.
Because the basic demographics for all of the trauma
ICU admissions in the 4 years were not significantly
different, this variance is not explained. VTE in the
moderate-risk group accounted for 4 PE, 1 case of
which was fatal. With the favorable experience in the
high-risk categories with the use of LMWH,
increased use of LMWH in the moderate-risk group
is suggested. With an increased use of LMWH,
increased cost requires consideration when used in
addition to sequential compression. Certain factors
might offset drug cost. As confidence and use of
LMWH increases, the need for surveillance VDUS
might decrease. Also, early conversion of patients to
warfarin PRx can be considered as soon as a reliable
route of enteral feeding is established.
Most of our cases of VTE involved thrombi in
the proximal veins, and only 10 of 30 documented
DVT cases were isolated to the calf. Of these, 60%
were discovered by means of VDUS. Once found,
however, such calf thrombi require attention. Loher
et al42 have documented the tendency of crural
thrombi to propagate. A number of studies have
implicated infracrural thrombi as the sole source of
PE.43-45 Currently, we advise upgrading the method
of PRx, or therapy, consonant with the clinical status
when the calf vein thrombi are found. This would
include addition of LMWH.
This observation of numerous calf thrombi in
addition to proximal thrombi confirms the use of
surveillance VDUS in trauma patients. Our selective
use of VDUS is consistent with the recommenda-
tions of Meyers et al,10 Napolitano et al,11 and
Knudson.4 The frequency of “unsuspected” DVT in
the current series, including 5 of 25 in proximal
vessels, is comparable with other reports and further
supports the wisdom of surveillance. The current
findings do not support a purely clinical approach to
VTE PRx as advocated by others.46 Our limited use
of intracaval filters reflects our concern for compli-
cations as documented by Patton.41 We support
Greenfield’s opinion that DVT is the primary
problem.47 Cava filter placement seems to be the
safest option when other methods are not applicable
or contraindicated in high-risk situations.
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The risk scoring system functions well on a day-
to-day basis and can be applied easily by various
observers. The overall occurrence of VTE after 1993
was relatively constant because the diagnosis of silent
VTE was enhanced by increased use of surveillance
VDUS in period 2. PE were absent in period 2,
possibly related to the intensification of PRx and
efforts at early diagnosis of DVT. We have been
cautious in interpretation of this clinical study
involving the patients who were typical and hetero-
geneous and variations in staff management in a
trauma center. A randomized study that focuses on
moderate-risk PRx appears indicated.
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Dr. Kenneth E. McIntyre Jr (Galveston, Tex.) The
purpose of this study, as stated by the authors, was to eval-
uate the use of standardized risk factors for venous throm-
boembolism in trauma patients, to develop guidelines for
the use of venous duplex ultrasound scanning for surveil-
lance, and to study the use of single-method and multiple-
method prophylaxis of venous thromboembolism. This
study is relevant because pulmonary embolism has been
observed in as many as 22% of patients for trauma and is
the third most common cause of death in those patients
who survive more than 24 hours. The challenge is formi-
dable: to develop effective prophylaxis for venous throm-
boembolism in a patient population that may have a
higher than expected risk of bleeding.
The subjects of this study were patients for trauma who
were admitted to the intensive care unit of a level II trauma
center in Northen Nevada. During period 1 from 1993 to
1995, a retrospective review of all documented cases of
venous thromboembolism and a correlation with the pres-
ence of known risk factors were performed. The authors
modified the International Society for Cardiovascular
Surgery/Society for Vascular Surgery risk factors and did
not include pregnancy or postpartum states, hormonal
therapy, or prethrombotic states as additional risk factors.
On the basis of these data, the authors devised 3 risk cate-
gories (low, moderate, high) and made recommendations
for deep venous thrombosis prophylaxis to be evaluated
prospectively during period 2, in 1996. Patients considered
to be at low risk received no prophylaxis, those considered
at moderate risk received leg compression devices, and
those considered at high risk received both leg compres-
sion devices and low molecular weight heparin, or
Enoxaparin. They compared the incidence rates of venous
thromboembolism for every year in each risk category and
recorded the prophylaxis measures used. All of the docu-
mented cases of venous thromboembolism occurred in the
moderate-risk and high-risk groups.
There are a few problems with this study, and I will try
to elucidate them for you. This group was not homoge-
neous because of the nature of the injuries and because 10
different surgeons were responsible for the care. All of the
patients did not undergo routine duplex scanning at
recommended times. It was only advised when prophylaxis
was not possible, and it is unclear from the manuscript
exactly what prompted ordering of the duplex scanning.
Because all patients did not undergo routine duplex
surveillance, the true incidence rate of venous throm-
boembolism as related to risk factors was unknown or at
best underestimated. Only selected patients who were
admitted to the intensive care unit for trauma were evalu-
ated concurrently, and apparently, once patients left the
hospital, they were not evaluated further. There was no
standard protocol for prophylaxis either. Compliance with
recommended guidelines occurred in only 85% of the
cases. Because routine duplex scanning was not done, it
was also difficult to evaluate the efficacy of prophylaxis.
Vena caval filters were used so infrequently that evaluation
of them as a tool for prophylaxis could not be done.
Are there positive attributes of this study? The risk strat-
ification that was used seemed to be effective in predicting
thromboembolism and seemed applicable for personnel
treating the patient for trauma. The surveillance program,
which was expanded during period 2, contributed to the
diagnosis of silent proximal deep venous thrombosis and
may have contributed to the reduction in pulmonary
embolism. Thromboembolism prophylaxis may not have
been as successful as predicted because of prolonged inter-
vals between injury and initiation of prophylaxis.
I have several questions for the authors.
1. Was a single negative duplex scanning considered
adequate for patients without thromboembolism
prophylaxis, or were these patients scanned more
than once during their hospitalization? 
2. Were patients followed-up once they left the
hospital? 
3. If so, did any patients develop venous throm-
boembolism after they went home?
4. Why did 78% of patients in period 1 sustain
venous thromboembolism despite some form of
prophylaxis?
5. Why were sequential compression devices alone
apparently unsuccessful in preventing venous
thromboembolism?
6. How long after injury was thromboembolism
prophylaxis begun, and when was it terminated?
7. What was the cost of prophylaxis when Enoxaparin
was used?
8. What treatment are you advising for patients
with tibial vein thrombosis and no documented
extension into the popliteal vein?
9. How did you follow patients with casts, dress-
ings, or open wounds on the legs?
10. What is your current recommendation for venous
duplex surveillance in patients with trauma?
The authors have attempted to predict which patients
with trauma are at risk for thromboembolism by using a
standard risk factor analysis that seems to have some merit.
However, because of a lack of following recommended
protocols for routine duplex surveillance and standard
prophylaxis, I am not convinced of the type of prophylaxis
for venous thromboembolism that is preferred. Moreover,
the strong recommendation of the authors for the use of
Enoxaparin in patients with moderate risk cannot be justi-
fied on the basis of their data. I would encourage the
authors to continue their work with protocols for duplex
surveillance at standard times and routine prophylaxis
measures for each risk category. In addition, patient follow-
up after hospitalization is important to document the
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natural history of patients for trauma with and without
thromboembolism after intensive care unit admissions.
Dr. H. Treat Cafferata. Your first question asks
whether a single negative duplex scanning is adequate. We
thought is was not. The scannings were indicated in the
patients usually because the patients had head injuries and
would not tolerate Enoxaparin or because the neurosur-
geons would not permit us to use Enoxaparin. Those
patients were followed-up at least at the end of the 1st
week and hopefully at 1-week to 2-week intervals. I do not
think that there is any established protocol for how often
venous Doppler ultrasound scanning should be done, and
in our institution, it costs the patient approximately $500
for each scan. So, this whole study tried to design reason-
able boundaries at least for doing these procedures and
keeping within the cost controls that exist.
Our patients were followed-up until discharge. As you
know, there is much open space in Nevada. Many of the
accidents occur with tourists as single-car rollovers in the
middle of nowhere. Follow-up after discharge is difficult
as they leave our community and return home.
If no deep venous thrombosis was documented in the
intensive care unit, the patients were followed-up on the
floor by the trauma nurse coordinators. We did not have
any incidences of which we are aware of people developing
this at home. I understand there are a number of papers
that advocate this.
The prophylaxis therapy was begun as soon as possible
after injury. Sequential devices whenever possible were put
into the operating rooms. The Enoxaparin was started at
least within 36 hours if at all possible. Again, as I say, there
were other factors that governed it.
As far as tibial veins are concerned, our treatment recom-
mendations are pretty much on the basis of the conditions
under which they are documented. So, if the patient was one
of those in the low-risk or moderate-risk category that had
not had any form of therapy, we would recommend at least
sequentials or prophylactic heparin levels.
If they developed where the patient had sequentials or
was on an anticoagulant, we probably would recommend
the next step of therapy. There are documented issues in
some people that these will embolize in the pulmonary
system. Even Norman Browse says that they are nonfatal,
but that small embolus could be fatal in a trauma patient
on a ventilator with adult respiratory distress syndrome.
So, we are a little aggressive about that.
Why do sequentials not work? Part of the reason is
because they are not always used on the floor. Another
part of the reason is that they are just not totally effective.
How do we deal with patients with bandages, casts, or
external fixators? Well, we deal the best we can. We are just
trying to treat the patient as we see them. So, we do not
always have perfect data, but we cannot always get that.
Dr. Kaj H. Johansen (Seattle, Wash.). Kudos to Dr.
Cafferata and colleagues for confronting an important
issue that is currently being pursued primarily in the
natural history realm.
It is with some alarm, therefore, that I hear what I
believe is an uncritical assumption of the value of low
molecular weight heparin as a prophylactic agent. I am
aware of the data on which this is based, but I am unclear
whether the statistical significance that suggests the
benefit of low molecular weight heparin over unfraction-
ated heparin is equalled by a clinical significance as well.
I am not at all sure that, at pennies rather than many
hundreds of dollars, we should not be simply giving these
patients unfractionated heparin if in-hospital prophylaxis is
what we have in mind.
Dr. Cafferata. Thank you. You are right. Although I
am not sure exactly, I was told that it cost our hospital
approximately $17 a dose for Enoxaparin. This is, of
course, well above what is cost effective in Canada. In fact,
it is almost three times that. However, all of the data in the
orthopedic literature and in a few current trauma studies
suggest that the superiority does lie with low molecular
weight heparin.
So, for the patients at high risk, I do not feel that there
is a problem there. As soon as we get these people to
where there is a reliable enteral route, we will start to
switch to Coumadin.
